Phase II trial of Cisplatin and Irinotecan treatment as palliative-intended chemotherapy for previously untreated advanced thymic carcinoma

Phase 2

• Conditions: thymic carcinoma

• Registration Number: JPRN-UMIN000012175
• Lead Sponsor: Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital

Brief Summary

o patient was enrolled.

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2013-11-30
• Study Completion: 2017-03-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 0

Inclusion Criteria

Not provided

Exclusion Criteria

1. With concurrent active cancer 2. Serious uncontrolled infections 3. With fever at more than 38 degree in Celicius 4. Lactating, pregnant or possibly pregnant women, or those willing to become pregnant 5. 6. 7. With malignant pleural, peritoneal effusion requiring drainage or pericardial effusion 6. With sever complication associated with operation 7. Under continuous steroid therapy 8. With uncontrolled diabetes melitus 9. With uncontrolled hypertension 10 Unstable angina or previous history of myocardial infarction within six months 11. With interstitial pneumonitis or pulmonary fibrosis detectable on chest X-ray

Study & Design

• Study Type: Interventional
• Study Design: Not specified